Dulaglutide 0.75mg subcutaneous injection: Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 1 to 14 days prior to surgery
Study summary
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care.
Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* Planned elective intermediate to high risk non-cardiac surgery
* Anticipated to remain hospitalized for at least one night after surgery
* Voluntarily agrees to participate by providing written informed consent
Exclusion Criteria:
* History of symptomatic hypoglycemia within 1 month of recruitment
* History of pancreatitis
* Diabetic retinopathy
* Personal or family history of medullary thyroid carcinoma (MTC)
* Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
* Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment
* Stroke or transient ischemic attack within 1 month of recruitment
* Known severe liver disease (Child-Pugh B or C)
* Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation \< 15 mL/min)
* Recent use of GLP-1 RA within 1 month of recruitment
* Known allergy or hypersensitivity to GLP-1 RA
* Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding
* Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)
Primary outcome measure(s)
Proportion of patients with MINS — Within 72 hours after surgery Defined as any elevation in troponin T \>= 14ng/L
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.